![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 27, 2026
Progress in geriatric oncology, reflections on regulatory complexity, and an exciting new trial in small cell lung cancer
February 27, 2026
This phase 2 trial is evaluating whether broccoli sprout extract (sulforaphane) will reduce the risk of melanoma returning
February 27, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
February 27, 2026
Liquid biopsies are now permitted for eligibility determination, while trial participants may use progression biopsies to explore treatment options
February 27, 2026
The latest clinical trial findings in breast cancer, leukemia, lymphoma, lung cancer, NCI-MATCH, and prostate cancer
February 27, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
January 30, 2026
The co-chairs reflect on last year's key research advances and highlight priorities for 2026
January 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for older adults with early-stage melanoma
January 30, 2026
The new objective is to identify biomarkers associated with malignant risk in pancreatic cysts, requiring current participants to reconsent
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
January 30, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management